Cancer Patients Given Wrong Dose of Medication For 3 Years

St. Vincent's hospital has begun informing the surviving patients that oncologist John Grygiel had been prescribing the same dosage without any test results.

In a prestigious hospital, dozens of Australian cancer patients have reportedly received less than the recommended dosage of a chemotherapy drug over a three year period.

While the problem has been known for some time, it is only now that St. Vincent's hospital has begun informing the surviving patients and their families that oncologist John Grygiel had been prescribing the same dosage for head and neck cancer without adjusting to their individual test results, Xinhua quoted Australia's national broadcaster as saying.

Mutations in HPV-Positive Throat Cancer Patients Who Smoke
Heavy and light smokers who develop HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) may inform decisions related to treatment intensity.

‘Oncologist John Grygiel had been prescribing the same dosage for head and neck cancer without adjusting to their individual test results.’

ABC reported that all 70 patients were administered the incorrect dosages for up to three years, and in some cases were given as little as 50 percent of the required dose. The usual dosage for common head and neck cancers is between 200 and 300 mg of the drug, but Grygiel gave a flat 100 mg dosage.

"I think that he felt that the dose he prescribed was genuinely effective and caused less side effects for patients," St. Vincent's hospital director of cancer services Richard Gallagher said.

"(But) I still don't understand where the mechanism or thought came from," he said. "I'm not happy this has gone on. I freely admit there's clearly a breakdown in clinical governance."

T-Cell Therapy Targeting Tumor Gene Mutations Could Be a Better Cancer Treatment
T cells are special forces of the immune system that patrol the body and are equipped with T cell receptors molecules.

Source-IANS

New Study on Connection Between Anal Cancer and Human Papillomavirus
A study demonstrating a connection between anal cancer and HPV infection has been published by researchers at Women & Infants Hospital, a Care New England hospital.

Immune-Targeting Anti-Tumor Drug Combo Shows Promise for Treating Lung Cancer
Moffitt has initiated a multicenter phase 1b clinical trial to determine the safety and efficacy of a new drug combination for non-small cell lung cancer.